Article

Nano-Sized Extracellular Vesicles Secreted from GATA-4 Modified Mesenchymal Stem Cells Promote Angiogenesis by Delivering Let-7 miRNAs

Min Gong 1,2, Min Wang 1,3, Jie Xu 1, Bin Yu 1, Yi-Gang Wang 1, Min Liu 1, Muhammad Ashraf 4 and Meifeng Xu 1,*

1 Department of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA; gongmin0794@suda.edu.cn (M.G.); wang.min1@mayo.edu (M.W.); xuje@ucmail.uc.edu (J.X.); binyu76@gmail.com (B.Y.); wanyy@ucmail.uc.edu (Y.-G.W.); lium@ucmail.uc.edu (M.L.)
2 Department of Neonatology, Children’s Hospital of Soochow University, No. 92 Zhongnan Street, Suzhou 215025, China
3 Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
4 Department of Medicine, Cardiology, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; mashraf@augusta.edu
* Correspondence: meifeng.xu@uc.edu; Tel.: +1-(513)-558-4725

Abstract: We demonstrated previously that extracellular vesicles (EVs) released from mesenchymal stem cells (MSCs) play a critical role in angiogenesis. Here, we examine whether this pro-angiogenic efficacy is enhanced in EVs derived from MSCs overexpressing GATA-4 (MSCGATA-4). Methods and Results. EVs were isolated from MSCGATA-4 (EVGATA-4) and control MSCs transduced with an empty vector (EVnull). EVs from both cell types were of the same size and displayed similar molecular markers. Compared with EVnull, EVGATA-4 increased both a tube-like structure formation and spheroid-based sprouting of human umbilical vein endothelial cells (HUVECs). The EVGATA-4 increased the numbers of CD31-positive cells and hemoglobin content inside Matrigel plugs subcutaneously transplanted into mice for 2 weeks. Moreover, EVGATA-4 encapsulated higher levels of let-7 family miRs compared to EVnull. The transfer of exosomal let-7 miRs into HUVECs was recorded with an accompanied down-regulation of thrombospondin-1 (THBS1) expression, a major endogenous angiogenesis inhibitor. The loss-and-gain of function studies of let-7 miRs showed that let-7f knockdown significantly decreased EVGATA-4-mediated vascularization inside Matrigel plugs. In contrast, let-7f overexpression promoted HUVEC migration and tube formation. Conclusion. Our results indicate that EVs derived from genetically modified MSCs with GATA-4 overexpression had increased pro-angiogenic capacity due to the delivery of let-7 miRs that targeted THBS1 in endothelial cells.

Keywords: extracellular vesicles; mesenchymal stem cells; GATA-4; angiogenesis; let-7

1. Introduction

Therapeutic angiogenesis has been recognized as a very important strategy for treating ischemic diseases such as peripheral and coronary vascular disease, cerebral infarction, and critical limb ischemia. Mesenchymal stem cells (MSCs) are widely used in research and pre-clinical tests to treat ischemic diseases [1,2]. Indeed, results obtained from both in vitro and in vivo experiments confirm that MSCs can enhance new blood vessel formation [2–4]. Many studies, including ours, show that MSCs secrete paracrine factors, including extracellular vesicles (EVs), that orchestrate interactions within the cellular milieu to promote angiogenesis [3,5–10]. EVs are characterized as exosomes, microvesicles, and apoptotic bodies, according to the nomenclature established by the International Society for Extracellular Vesicles [11]. EVs, especially exosomes, are considered to play a critical role
in cardiac regeneration and protection [12–15] since they can recapitulate the regenerative and functional effects produced by their parent cells [9,16,17].

EVs are bi-lipid-layered vesicles containing proteins, mRNAs, and microRNAs (miRs) and can transfer their contents to the recipient cells to modulate the function of these cells [18–20]. miRs are small, evolutionarily conserved, well-characterized endogenous noncoding RNA molecules that can negatively regulate gene expression by targeting specific mRNAs, leading to degradation or translational repression [21]. Recent reports indicate that several miRs can promote angiogenesis [22–25]. The content of EVs can be altered by preconditioning parent cells. Pro-angiogenic exosomal miRs increase substantially following hypoxic/ischemic preconditioning [26,27]. More importantly, EVs derived from preconditioned stem cells have a high potential for increasing vascular density, reducing cardiomyocyte (CM) apoptosis and myocardial fibrosis [27], and increasing recruitment of cardiac progenitor cells to the infarcted heart [28]. EVs collected from stem cells transfected with specific miRs produce greater beneficial effects in protecting CM and regenerating infarcted myocardium [29,30].

GATA-4 is a zinc finger transcription factor that promotes myocardial regeneration [31]. GATA-4 is also considered as an anti-apoptotic factor implicated in regulating cell growth, differentiation, and survival. An inducible loss of GATA-4 severely depressed ventricular function accompanied by reduced CM replication and impaired coronary angiogenesis [32]. The peri-infarct intra-myocardial delivery of GATA-4 prevented adverse post-infarction remodeling through myocardial angiogenesis, anti-apoptosis, and stem cell recruitment [33]. Our previous studies suggest that the transduction of MSCs with GATA-4 (MSC\textsuperscript{GATA-4}) significantly promoted MSC-mediated ischemic myocardium salvage, which appeared not only due to increased MSC survival [34] and trans-differentiation [35] but also due to the protection of native CM and the promotion of angiogenesis through the enhanced paracrine effects of MSCs [5]. EVs derived from MSC\textsuperscript{GATA-4} (EV\textsuperscript{GATA-4}) are more effective at protecting CM from ischemic injury than EVs from empty vector-transfected MSC (EV\textsuperscript{null}) [18]. It is unclear whether EV\textsuperscript{GATA-4} promotes angiogenesis during the regeneration of ischemic myocardium. Given that miRs are encapsulated in MSC-derived EVs and that EVs can be regulated by the modification of their parent cells, we hypothesize that EV\textsuperscript{GATA-4} promotes angiogenesis via delivering pro-angiogenic miRs to recipient cells.

2. Materials and Methods
2.1. Animals
C57BL/6 mice were purchased from Charles River Laboratories. The experimental protocols are approved by The Animal Care Committee of the University of Cincinnati Institutional Animal Care and Use Committee. All animal experiments were conducted in accordance with the National Institutes of Health guide for the care and use of laboratory animals (NIH publication No. 85-23, Revised 1996). Mice were housed under specific pathogen-free laboratory conditions with optimal temperature, humidity, and photoperiods (12L:12D).

2.2. Generate Stable MSCs with GATA-4 Overexpression
MSC cell line C3H10T1/2 cells were purchased from ATCC (Manassas, VA, USA). MSCs were cultured with Dulbecco’s modified Eagle medium/Ham’s Nutrient Mixture F12 (DMEM/F12)(Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS) at 37 °C in humidified air with 5% CO\textsubscript{2} atmosphere. Stable MSCs with GATA-4 overexpression were generated using a pMSCV retroviral expression system (Clontech, Mountain View, CA, USA) carrying the GATA-4 gene open reading fragment and the GFP protein gene, and they were selected by puromycin, as we have done previously [18,34]. The control cells (MSC\textsuperscript{null}) were transduced using the same retroviral system with the GFP protein gene fragment only.
2.3. Isolation and Characterization of EVs

MSCs were first seeded at $3 \times 10^6$ per 15-cm plate in complete DMEM/F12 medium for 24 h. Then, the completed medium was replaced with 15 mL of serum-free medium. After 24 h, the culture medium was obtained, and EV were collected using ultracentrifugation method shown as Figure 1. The morphology of EVs was examined under transmission electron microscope (JEOL JEM-1230) (JEOL, Peabody, MA, USA), as described previously [36]. The size and concentration of EVs was evaluated using dynamic light scattering in a particle- and molecular-size analyzer (Zetasizer Nano ZS)(Malvern Instruments, Malvern, UK). The expression of CD9, CD63, HSP70, and calnexin in EVs was quantified using Western blotting. The amount of protein in EVs was determined using the BCA method (Thermo Fisher Scientific, Waltham, MA, USA).

![Figure 1](image-url).

2.4. Real-Time PCR

Total RNA was extracted from EVs using mirVana™ miR isolation kit (Ambion, Austin, TX, USA) following manufacturer’s protocol. cDNA synthesis and quantitative PCR were performed using the miScript PCR Starter Kit (Qiagen, Germantown, MD, USA). In brief, 1 µg total RNA obtained from each preparation was used for the first-stand cDNA reverse transcription in the 20 µL system. Real-time PCR was performed with specific primers (Qiagen) using a iQ5 real-time PCR system (Bio-Rad, Hercules, CA, USA), according to the manufacturer’s instructions. Data were normalized to the results obtained with primers specific to β-actin and U6, or in the case of EVs by using the synthetic Spike-In control (Ce-miR-39) as an internal control.

2.5. Western Blotting

Proteins were extracted using nuclear (Pierce) (Rockford, IL, USA) (for GATA-4) and total protein extraction reagents (Qiagen) according to the manufacturer’s protocol. The proteins were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
(SDS-PAGE) and transferred to 0.45 µm polyvinylidene difluoride membrane (Millipore, Burlington, MA, USA). The membranes were blocked with 5% skim milk in TBST at room temperature for 1 h and incubated with primary antibodies of anti-CD9, anti-calnexin (Abcam, Branford, CT, USA), anti-CD63 (Applied Biological Materials, Richmond, BC, Canada), anti-HSP70 (Cell Signaling, Danvers, MA, USA), anti-GATA-4 (Santa Cruz, Santa Cruz, CA, USA), and anti-THBS1 (Sigma-Aldrich, Saint Louis, MO, USA) at 4 °C overnight. After washing three times with TBST, the membranes were probed with HRP-conjugated secondary antibodies (Cell Signaling), respectively, at room temperature for 1 h and visualized using ECL Plus kit (GE Healthcare, Cincinnati, OH, USA). The expression of a specific protein was normalized with histone H3 and β-actin.

2.6. Angiogenesis In Vitro

(1) Tube formation by human umbilical vein endothelial cells (HUVECs) was examined in a 24-well plate coated with Matrigel™ (BD Biosciences, San Jose, CA, USA). HUVECs (3 × 10^4) were seeded on top of Matrigel™. EVs were added into the medium, and plates were placed into an incubator. Images were taken by a phase-contrast microscopy (Olympus, Center Valley, PA, USA) or an Incucyte Imaging System (Essen, Ann Arbor, MI, USA), and the cumulative tube length of the network structure was measured by randomly selected five microscopic fields using Image J software (National Institutes of Health, Bethesda, MD, USA).

(2) HUVECs spheroids were generated as described previously [36]. Briefly, GFP+ HUVECs were trypsinized and collected in endothelial cell growth medium (Cell Applications) containing 0.2% carboxymethylcellulose (Sigma). HUVECs (500 cells/100 µL/well) were plated in non-adherent round-bottom 96-well plates (Greiner, Monroe, NC, USA) for 16 h. The spheroids were then harvested and embedded into Matrigel™ basement membrane matrix (BD Bioscience) in endothelial cell serum free defined medium (Cell Applications, San Diego, CA, USA). The cumulative sprout length per spheroid was calculated by measuring from the farthest migrating point to its tangential line position of each sprout using the segmented lines tool in Image J, version 1.53k (National Institute of Mental Health, Bethesda, MD, USA).

(3) For the endothelial cell migration test, HUVECs were seeded in 96-well plates at a density of 2 × 10^5 cells/well. When HUVECs had become a monolayer, scratches were generated in the center of the well using a sterile plastic 200 µL micropipette tip. Images were photographed at 0 and 12 h, and the width of scratch was measured using Image J software.

2.7. Angiogenesis In Vivo

The blood vessel formation in the transplanted Matrigel™ plug was assayed in mice, as described previously [23,36]. Briefly, C57BL/6 mice (6–8 weeks old) were anesthetized with ketamine/xylazine (100/10 mg/kg, IP). Matrigel™ (BD Biosciences) (500 µL), mixed with EVs and 15 U of heparin (Sigma), was subcutaneously injected along the abdominal midline. Two weeks later, plugs were excised, embedded in Optimal Cutting Temperature Compound (OCT), and cut into 7 µm sections. The infiltration of endothelial cells into Matrigel™ plugs was determined by immunostaining for CD31. All the CD31 positive cells were quantified as mean pixel density obtained from the image analysis of six random microscopic fields using Image J software. In another cohort of animals, the red blood cells contained inside Matrigel™ plugs were evaluated by determining hemoglobin content (Drabkin’s reagent kit) (Sigma). Briefly, the Matrigel™ plug was homogenized in deionized water and centrifuged. The hemoglobin concentration in the supernatant was determined by the Drabkin assay. The standard curve was generated using Stanbio™ Cyanmethemoglobin Standard (Stanbio Laboratory, Boerne, TX, USA).
2.8. Immunofluorescence Staining

Immunofluorescence staining for GATA-4 and CD31 was carried out, as described previously [18]. Briefly, cells or slices of the Matrigel™ plug were fixed with 4% paraformaldehyde for 30 min and then blocked with 10% goat serum containing 0.3% Triton X-100 for 1 h. The primary antibodies of anti-GATA-4 (Santa Cruz) or anti-CD31 (BD Pharmingen™, San Diego, CA, USA) were incubated at 4 °C overnight. Antibody reaction was visualized with dylight 488- or dylight 594-conjugated secondary antibodies (Molecular Probes, Eugene, OR, USA). Nuclei were stained with 4′, 6-diamino-2-phenylindole (DAPI). Fluorescence images were obtained with an Olympus fluorescence microscope (Olympus, Center Valley, PA, USA).

2.9. Internalization of EVs and Transfer of Let-7f

EVs derived from MSCs overexpressing CD63-GFP (MSCCD63-GFP) were used to track internalization. Lentivirus carrying CD63-GFP fusion protein (System Biosciences, Palo Alto, CA, USA) was used to transfect MSCs and get MSCCD63-GFP, according to the manufacturer’s instructions. MSCCD63-GFP was cultured in serum-free DMEM medium (Corning, Corning, NY, USA) for 48 h, and the medium was collected for EV isolation. EVs (EVCD63-GFP) derived from MSCCD63-GFP were added to HUVECs and cultured for 24 h. EV internalization was visualized and photographed using an Olympus fluorescence microscope.

To determine the transfer of exosomal miR, pre-miR precursor (mmu-let-7f) (Ambion, Austin, TX, USA) was labeled with Label IT siRNA Tracker Cy3 Kit (Mirusbio, Madison, WI, USA), according to the manufacturer’s instructions. MSCCD63-GFP were transfected with 10 nM of Cy3-labeled pre-let-7f (MSCCD63-GFP/Cy3-let−7f) using X-tremeGENE 9 DNA Transfection Reagent (Roche Life Science, Indianapolis, IN, USA) for 24 h. The medium was replaced with fresh serum-free DMEM medium (Corning) and cultured for another 48 h. EVs were collected from the medium of cultured MSCCD63-GFP/Cy3-let−7f (EVCD63-GFP/Cy3-let−7f) and added to HUVECs for 24 h. The transfer of Cy3-let-7f was tracked using an Olympus fluorescence microscope.

2.10. Gain- and Loss-Function of Let-7f

To generate overexpressing let-7f HUVECs, pre-let-7f-copGFP plasmid or scrambled plasmid (System Biosciences Company, Mountain View, CA, USA) was first mixed with packaging plasmids and co-transfected into 293Ta cells according to the manufacturer’s instructions. Then, HUVECs were infected with the high titer lentiviral particles of let-7f (HUVEClet−7f) or the scrambled control (HUVECScrambled) for 24 h. After infection with the lentiviral particles, HUVECs positive for GFP fluorescence were selected using puromycin. Similarly, knockdown of let-7f in MSCGATA−4 was performed by transfecting MSCs with the high titer lentiviral particles of anti-let-7f (MSCGATA−4 + anti-let−7f) and the scrambled control (MSCGATA−4 + Scrambled) using anti-let-7f expression plasmid pEZX-AM03 with the mCherry red fluorescence reporter gene and its scrambled control plasmid (Genecopoeia, Rockville, MD, USA). MSCs positive for mCherry red fluorescence were selected using hygromycin.

2.11. Luciferase Assay

TargetScan was used to find the potential let-7 target sites. This shows that the 3′-UTR of THBS1 contains the conserved let-7 binding site. The miTarget™ dual luciferase reporter vector (pEZX-MT06) containing the full-length 3′-UTR sequence of the THBS1 and the control vector for pEZX-MT06 (mutated vector) were purchased from GeneCopoeia. The HUVECs were seeded in 24-well plates and transfected with THBS1 3′-UTR luciferase reporter vector or the mutated vector pEZX-MT06 (GeneCopoeia) using X-tremeGENE 9 DNA Transfection Reagent (Roche Life Science) according to manufacturer’s protocol. Then, EVnull or EVGATA−4 were added into the transfected cell and cultured for 48 h. Cells
were lysed and collected, and Firefly and Renilla luciferase activities of cell lysate were measured using a Luc-Pair™ Duo-Luciferase Assay Kit (GeneCopoeia).

2.12. Statistical Analysis

Data are expressed as mean ± SEM unless otherwise indicated. Statistical analyses were performed by one-way ANOVA or two-tailed Student t-test to measure significant differences between groups. Results were considered statistically significant when p < 0.05.

3. Results

3.1. Characterization of MSC\textsuperscript{GATA-4} and EV\textsuperscript{GATA-4}

Both MSC\textsuperscript{GATA-4} and MSC\textsuperscript{null} were GFP positive, and GATA-4 staining was stronger in MSC\textsuperscript{GATA-4} compared to that in MSC\textsuperscript{null} (Figure 2A). Quantitative RT-PCR indicated that the mRNA of GATA-4 was significantly increased in MSC\textsuperscript{GATA-4}, compared to that in MSC\textsuperscript{null} (Figure 2B). EVs derived from MSC\textsuperscript{GATA-4} and MSC\textsuperscript{null} were morphologically diverse round-shaped entities under transmission electron microscope (Figure 2C). The average size of EV\textsuperscript{GATA-4} (54.7 ± 3.3 nm) determined by dynamic light scattering was comparable to that of EV\textsuperscript{null} (53.8 ± 2.3 nm) (Figure 2D). There was no significant difference in the expression levels of three specific molecular markers of EVs, CD9, CD63, and HSP70, between EV\textsuperscript{null} and EV\textsuperscript{GATA-4} (Figure 2E). The purification of EVs was determined by Western blot analysis, and no expression of Calnexin (a cell positive marker) was found in EVs (Figure 2F).
3.2. EVGATA−4 Promotes Angiogenesis

To determine the optimal concentration of EVs and duration, EVs (0–36 µg/mL) and VEGF (18ng/mL) were added into HUVEC culture medium for testing a tube-like structure formation. The plates were placed into the incubator equipped with an Incucyte Imaging System. The images were captured every two hours for 36 h. The tube-like structure formation of HUVECs reached its peak after 16 h. The real-time images of different treatments are shown in Figure 3A. The effect of EVs on promoting tube-like structure formation at 18 µg/mL was similar to the cells treated with VEGF at 18 ng/ml. Therefore, this concentration of EV, i.e., $10 \times 10^9$ EV/µL (NTA results: $5.54 \times 10^8 \pm 3.25 \times 10^7 / \mu g$ protein), was used in the following experiments. The cumulative tube length was significantly longer ($49.29 \pm 2.32 \text{mm} / 5.375 \text{mm}^2$) in HUVECs treated with EVGATA−4 than those treated with BSA in the same protein amount (CON, $20.88 \pm 2.87 \text{mm} / 5.375 \text{mm}^2$), or with EVnull ($35.51 \pm 4.11 \text{mm} / 5.375 \text{mm}^2$) (Figure 3B). Similarly, the sprout length...
per spheroid in HUVECs treated with EV$^{\text{GATA-4}}$ was significantly longer ($469.59 \pm 94.19 \mu m/\text{spheroid}$) than that treated with BSA ($85.41 \pm 32.04 \mu m/\text{spheroid}$), or with EV$^{\text{null}}$ ($221.46 \pm 34.40 \mu m/\text{spheroid}$) (Figure 3C).

**Figure 3.** EV$^{\text{GATA-4}}$ promoted tube-like structure formation and spheroid sprouting. (A) EVs mediated the tube-like structure formation in a concentration-related manner. (B) Representative images of capillary-like tube formation and quantitative analysis of the total tube length. (C) Representative images of HUVEC spheroids sprouting and quantitative analysis of the cumulative sprout length per spheroid. $^\# p < 0.05$ vs. CON (BSA); $^* p < 0.05$ vs. EV$^{\text{null}}$. 
To further examine whether EV\textsuperscript{GATA−4} promotes angiogenesis in vivo, Matrigel\textsuperscript{TM} plugs containing EVs were transplanted into mice. Matrigel\textsuperscript{TM} plugs contained EV\textsuperscript{GATA−4} were observed to have the deepest red gross appearance after transplantation into mice for 2 weeks (Figure 4A). The hemoglobin content in the plugs containing EV\textsuperscript{GATA−4} (22.08 ± 6.65 µg/mg plug, \(n = 9\)) was significantly higher than the plugs with BSA control (2.63 ± 1.46 µg/mg plug, \(n = 8\)), or EV\textsuperscript{null} (11.17 ± 4.30 µg/mg plug, \(n = 9\)) (Figure 4B). Neovascularization in Matrigel\textsuperscript{TM} plugs was further visualized by immunofluorescence staining specific to CD31. As shown in Figure 4C, the cells positively stained for CD31 in the plugs containing EV\textsuperscript{GATA−4} had significantly more staining than the plugs containing BSA control, or EV\textsuperscript{null}.

**Figure 4.** EV\textsuperscript{GATA−4} promoted angiogenesis in vivo. (A) The representative gross appearance of Matrigel\textsuperscript{TM} plugs, which were implanted subcutaneously in mice for 14 days. (B) Hemoglobin content in the Matrigel\textsuperscript{TM} plugs. (C) Immunofluorescence staining of CD31 in the sections of Matrigel\textsuperscript{TM} plugs and quantification of the CD31-positive cells. \# \(p < 0.05\) vs. CON (BSA); \* \(p < 0.05\) vs. EV\textsuperscript{null}. 
3.3. \textit{EV}^{GATA-4} Transfer Let-7 miRs to HUVECs

The expression of miRs in \textit{EV}^{GATA-4} was compared with \textit{EV}^{null} using the next-generation miRNA sequence. There were 44 miR, out of a total of 358 miR, that were upregulated in \textit{EV}^{GATA-4}. Among these upregulated miR, let-7 family (including miR-3596) were the ones with significantly higher levels expressed in \textit{EV}^{GATA-4} than in \textit{EV}^{null} (Table 1).

**Table 1.** The expression of let-7 in EVs.

| miRs      | \textit{EV}^{GATA-4} | \textit{EV}^{null} |
|-----------|----------------------|-------------------|
| miR-3596d | 145,686              | 47,721            |
| let-7f    | 132,442              | 43,383            |
| miR-3596a | 67,251               | 11,255            |
| let-7a    | 66,997               | 11,385            |
| miR-3596b | 60,521               | 19,136            |
| let-7d    | 55,019               | 17,397            |
| let-7f-1  | 32,765               | 10,810            |
| miR-3596c | 20,236               | 8314              |
| let-7e    | 19,317               | 7936              |
| let-7a-1  | 15,939               | 2910              |
| let-7a-2  | 15,429               | 2587              |
| let-7f-2  | 10,254               | 4072              |
| let-7e    | 4673                 | 2479              |

Quantitative RT-PCR was used to examine the expression of let-7a, let-7d, let-7e, and let-7f in EVs. The expression of these let-7 miRs was upregulated by 2- to 3-fold in \textit{EV}^{GATA-4}, compared to those in \textit{EV}^{null} (Figure 5A). The expression of let-7a, let-7d, let-7e, and let-7f in HUVECs treated with \textit{EV}^{GATA-4} was significantly upregulated, compared to those treated with \textit{EV}^{null} after 16 h (Figure 5B). To demonstrate the internalization of EVs by HUVECs, EVs collected from MSCs overexpressing CD63 with GFP (\textit{EV}^{CD63-GFP}) were added to HUVEC culture. Six hours later, most of HUVECs exhibited green fluorescence and were strongly positive for CD63 by immunofluorescence staining (Figure 5C). Furthermore, we directly tracked the transfer of let-7f by using EVs collected from MSC^{CD63-GFP} that had also been transfected with Cy3-labeled pre-let-7f (\textit{EV}^{CD63-GFP/Cy3-let-7f}). As shown in Figure 5D, HUVECs treated with \textit{EV}^{CD63-GFP/Cy3-let-7f} for 24 h not only exhibited the signals of CD63-GFP but also showed Cy3-let-7f (red).
Figure 5. EVs mediated the transfer of let-7 miRs. (A) The up-regulation of let-7a, let-7d, let-7e, and let-7f in EVGATA-4 was evaluated by qRT-PCR. (B) The quantitative analysis of let-7 miRs in HUVECs treated with EVnull and EVGATA-4. (C) The HUVECs showed strong positivity for CD63 after culture with EVCD63-GFP. (D) Let-7f (red) was strongly expressed in HUVECs cultured with EVCD63-GFP/CY3-let-7f. *p < 0.05 vs. EVnull.

3.4. Transfer of Let-7f Play a Critical Role in EVGATA−4-Mediated Angiogenesis

To downregulate let-7f in EVs, anti-let-7f was transfected into MSCGATA−4. Let-7f expression was reduced significantly both in MSCGATA−4 + anti-let−7f and in EVs derived from these cells (EVGATA−4 + anti-let−7f), compared to the cells transfected with negative control (MSCGATA−4 + Scrambled) and EVs obtained from control cells (EVGATA−4 + Scrambled), respectively (Figure 6A). Meanwhile, the expression of let-7f was also significantly reduced in HUVECs treated with EVGATA−4 + anti-let−7f, compared to that in HUVECs treated with EVGATA−4 + Scrambled (Figure 6B). The cumulative tube length was significantly decreased in HUVECs treated with EVGATA−4 + anti-let−7f, compared to those treated with EVGATA−4 + Scrambled (Figure 6C). In vivo implantation of Matrigel™ plugs in mice for 2 weeks, and vasculature positively stained for CD31 in the plugs containing EVGATA−4 + anti-let−7f, was also significantly less than in plugs with EVGATA−4 + Scrambled (Figure 6D).
Figure 6. EVGATA-4-mediated angiogenesis was related to the expression of let-7. (A) The expression of let-7f in MSCG4 + anti-let-7f and EVG4 + anti-let-7f, as well as their control. (B) The expression of let-7f in HUVECs treated with EVG4 + anti-let-7f and EVG4-Scr. (C) Representative images of capillary-like tube formation and quantitative analysis of the total tube length following EV treatment. (D) Immunofluorescence staining of CD31 in the sections of Matrigel™ plugs, and the quantification of the CD31-positive cells. # p < 0.05 vs. MSCG4 + Scr; * p < 0.05 vs. EVG4 + Scr. (EVG4 + Scr = EVGATA-4 + scrambled; EVG4 + anti-let-7f = EVGATA-4 + anti-let-7f).

The analysis of computational miRs target prediction with microRNA.org and TargetScan revealed that the 3′ UTR of THBS1 contained the conserved let-7 family binding site (Figure 7A). To investigate whether EVs regulated the expression of THBS1 in HUVECs, HUVECs were transfected with miTarget™ dual luciferase reporter vector containing the full-length 3′ UTR sequence of the THBS1 and mutated 3′ UTR of THBS1, respectively. Then, these cells were treated with EVnull or EVGATA−4 for 48 h. The luciferase activity in HUVECs transfected with the THBS1-3′ UTR luciferase reporter vector was significantly inhibited after being treated with EVGATA−4, compared with that in HUVECs treated with EVnull (Figure 7B). However, the luciferase activity in HUVECs with mutated THBS1-3′ UTR was not affected under different treatments (Figure 7C). Western blotting results showed that the protein level of THBS1 was significantly reduced in HUVECs treated with EVGATA−4, compared with that in HUVECs treated with BSA (as a control) or EVnull (Figure 7D). Consistent with this, the protein level of THBS1 was increased by 1.7-fold in HUVECs treated with EVGATA−4 + anti-let-7f, compared to that in HUVECs treated with EVGATA−4 + Scrambled (Figure 7E).
Figure 7. Exosomal let-7 miRs functionally down-regulated the target gene THBS1 in HUVECs. (A) An example of complementarity between let-7 miRs and the THBS1 3′ UTR. (B,C) Quantitative data for dual-luciferase reporter assay in HUVECs treated with EVnull or EVGATA-4. (D) The THBS1 protein levels in HUVECs following different treatments determined by Western blotting. (E) The protein level of THBS1 in HUVECs treated with EVs. #p < 0.05 vs. CON (BSA); *p < 0.05 vs. EVnull; and @p < 0.05 vs. EVG4-Scr, respectively. (EVG4 + Scr = EVGATA-4 + Scrambled; EVG4 + anti-let-7f = EVGATA-4 + anti-let-7f).

Furthermore, the gain of function of let-7f in HUVECs was used to examine the direct effect of let-7 on angiogenesis. HUVECs were directly infected with lentiviral particles of let-7f (HUVEClet−7f) or scrambled control (HUVECScrambled) (Figure 8A). The expression of let-7f was increased by 8.1-fold in HUVEClet−7f, compared to that in HUVECScrambled (Figure 8B). Western blotting confirmed that let-7f overexpression significantly reduced the THBS1 protein level in HUVECs (Figure 8C). The elevated expression of let-7f was directly associated with the function of endothelial cells. The tube-like structure formation and the
migration of HUVEC<sub>let−7f</sub> (Figure 8D,E) were significantly promoted, compared to that in HUVEC<sub>Scrambled</sub>.

![Figure 8](image)

**Figure 8.** Let-7f overexpression in HUVECs promoted tube-like structure formation and migration. (A) Representative images of HUVECs with let-7f overexpression (HUVEC<sub>let-7f</sub>), and their negative control (HUVEC<sub>Scrambled</sub>). (B) The expression of let-7f in HUVECs. (C) The THBS1 protein in HUVECs transfected with let-7f. (D) Representative images of capillary-like tube formation and quantitative analysis of the total tube length. (E) Representative images of HUVEC migration and quantitative analysis. *p < 0.05 vs. HUVEC<sub>Scr</sub>. (HScr = HUVEC<sub>Scrambled</sub>, Hlet-7f = HUVEC<sub>let-7f</sub>.)

### 4. Discussion

In the present study, the pro-angiogenic effect of EV<sup>GATA−4</sup> was systematically examined. We found that: (1) EV<sup>GATA−4</sup> significantly increased angiogenesis, as determined in
tests using a tube-like structure formation and spheroid-based sprouting of HUVECs, as well as neovascularization in Matrigel™ plugs implanted in mice; (2) EV_{GATA}−4 transferred let-7 miRs down-regulated the expression of THBS1, an anti-angiogenesis protein in target cells. These results demonstrated that the transfer of let-7 miRs from EVs into endothelial cells played a critical role in EV_{GATA}−4-mediated angiogenesis.

Neo-angiogenesis is considered a prerequisite for tissue repair and functional recovery associated with stem cell therapy. Several laboratories have reported that EVs derived from MSCs improve cardiac function by increasing capillary density and directly promoting angiogenesis [37–41]. In this study, we systematically determined whether EVs derived from MSCs engineered with GATA-4 were more efficacious in promoting angiogenesis, compared to those derived from MSCs transfected with empty vector. Our results showed that EV_{GATA}−4 not only promoted tube-like structure formation and spheroid-based sprouting in vitro but also increased blood vessel formation in Matrigel™ plugs in vivo compared to those derived from control MSCs, which were transfected with an empty vector. Our results are consistent with previous reports that HUVECs can acquire MSC-derived EVs, resulting in an enhancement of in vitro proliferation, migration, and tube formation [39,42].

It is well known that EVs released from stem cells are enriched in miRs [43–46] and can promote angiogenesis via delivering various pro-angiogenesis miRs [47]. Our previous report [18] indicates that EVs released from GATA-4-engineered stem cells have much potential to protect cardiomyocytes and regenerate ischemic myocardium by releasing multiple miRs responsible for the activation of the cell survival and pro-angiogenesis signaling pathways. We have also demonstrated that exosomal transfer of pro-angiogenic miRs plays an important role in MSC-mediated angiogenesis and stem-cell-to-endothelial-cell communication [36]. In the present studies, we compared the expression of let-7 miR family in EV_{GATA}−4 with those in EV_{null}. Our results are consistent with a previous report that the expression of these miRs was upregulated in EVs derived from GATA overexpressing MSCs [48].

We selected let-7f, a member of the let-7 miR family, as an example to determine the role of the let-7 related signaling pathway in EV_{GATA}−4-mediated angiogenesis using gain-and loss-of-function approaches. We found that increased let-7 miRs played an important role in EV_{GATA}−4 mediated angiogenesis. It has been reported that let-7 miRs enhance angiogenesis through protecting microvascular endothelial cells [49]; preventing the dysfunction of endothelial progenitor cells [25]; promoting microvascular pericyte differentiation [24]; and regulating inflammation [50], as well as autophagy and apoptosis [51]. Bioinformatics analysis indicated the putative binding sites of let-7 miRs in the 3’ untranslated regions of THBS1 mRNA. Our studies directly demonstrate that THBS1 is one of the potential targets of let-7 miRs and that the pro-angiogenic effects of let-7 miRs might be associated with the down-regulation of THBS1 expression in endothelial cells. THBS1 is a secreted protein with a variety of biological features, including having a potent anti-angiogenic activity [52]. It inhibits angiogenesis either through direct effecting endothelial cell migration, proliferation, survival, and apoptosis [53], through antagonizing the activity of VEGF [54,55], or possibly by multiple coordinated actions.

In conclusion, our findings revealed that EVs secreted from GATA-4-overexpressing mesenchymal stem cells promoted angiogenesis via delivering let-7 miRs to endothelial cells, resulting in THBS1 downregulation. These results suggest that EV_{GATA}−4 could be a viable therapeutic candidate for the induction of therapeutic angiogenesis in wound healing and tissue regeneration, following ischemic events.

**Author Contributions:** Conceptualization, M.X. and M.G.; methodology, M.G., M.W., J.X. and B.Y.; software, M.G.; writing, M.G.; review and editing, M.X., M.L., M.A. and Y.-G.W.; funding acquisition, M.X.; All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R01HL105176, R01HL114654, and R01HL140962 (M.X.)
Institutional Review Board Statement: The animal study protocol was approved by The Animal Care Committee of the University of Cincinnati Institutional Animal Care and Use. (protocol # 20-11-03-01, approved at 28 January 2021).

Informed Consent Statement: Not applicable.

Data Availability Statement: The datasets generated and analyzed during the present study are available from the corresponding author upon reasonable request.

Conflicts of Interest: No conflict of interest, financial or otherwise, is declared by the authors.

References

1. Shafei, A.E.; Ali, M.A.; Ghanem, H.G.; Shehata, A.I.; Abdelgawad, A.A.; Handal, H.R.; ElSayed, A.S.; Ashaal, A.E.; Ali, M.M.; El-Shal, A.S. Mechanistic effects of mesenchymal and hematopoietic stem cells: New therapeutic targets in myocardial infarction. *J. Cell Biochem.* 2018, 119, 5274–5286. [CrossRef] [PubMed]

2. Hou, L.; Kim, J.J.; Woo, Y.J.; Huang, N.F. Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease. *Am. J. Physiol. Heart Circ. Physiol.* 2016, 310, H455–H465. [CrossRef] [PubMed]

3. Kinnaird, T.; Stable, E.; Burnett, M.S.; Lee, C.W.; Barr, S.; Fuchs, S.; Epstein, S.E. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. *Circ. Res.* 2004, 94, 679–686. [CrossRef] [PubMed]

4. Ertl, J.; Pichlsberger, M.; Tuca, A.C.; Wurzer, P.; Fuchs, J.; Geyer, S.H.; Maurer-Gesek, B.; Weninger, W.J.; Pfeiffer, D.; Bubalo, V.; et al. Comparative study of regenerative effects of mesenchymal stem cells derived from placental amnion, chorion and umbilical cord on dermal wounds. *Placenta* 2018, 65, 37–46. [CrossRef]

5. Li, H.; Zuo, S.; He, Z.; Yang, Y.; Pasha, Z.; Wang, Y.; Xu, M. Paracrine factors released by GATA-4 overexpressed mesenchymal stem cells increase angiogenesis and cell survival. *Am. J. Physiol. Heart Circ. Physiol.* 2010, 299, H1772–H1781. [CrossRef]

6. Santos Nascimento, D.; Mosqueira, D.; Sousa, L.M.; Teixeira, M.; Filipe, M.; Resende, T.P.; Araujo, A.F.; Valente, M.; Almeida, J.; Martin, J.P.; et al. Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms. *Stem Cell Res Ther.* 2014, 5, 5. [CrossRef]

7. Timmers, L.; Lim, S.K.; Hofer, I.E.; Arslan, F.; Lai, R.C.; van Oorschot, A.A.; Goumans, M.J.; Strijder, C.; Sze, S.K.; Choo, A.; et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. *Stem Cell Res.* 2011, 6, 206–214. [CrossRef]

8. Abreu, S.C.; Weiss, D.J.; Rocco, P.R. Extracellular vesicles derived from mesenchymal stem cells: A therapeutic option in respiratory diseases? *Stem Cell Res. Ther.* 2016, 7, 53. [CrossRef]

9. Ibrahim, A.G.; Cheng, K.; Marban, E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. *Stem Cell Reports.* 2014, 2, 606–619. [CrossRef]

10. Wang, N.; Chen, C.; Yang, D.; Liao, Q.; Luo, H.; Wang, X.; Zhou, F.; Yang, X.; Yang, J.; Zeng, C.; et al. Mesenchymal stem cells-derived extracellular vesicles, via miR-210, improve infarcted cardiac function by promotion of angiogenesis. *Biochim. Biophys. Acta.* 2017, 1863, 2085–2092. [CrossRef]

11. Lotvall, J.; Hill, A.F.; Hochberg, F.; Buzas, E.I.; Di Vizio, D.; Gardiner, C.; Gho, Y.S.; Kurochkin, I.V.; Mathivanan, S.; Quesenberry, P.; et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the International Society for Extracellular Vesicles. *J. Extracell Vesicles.* 2014, 3, 26913. [CrossRef] [PubMed]

12. Barile, L.; Milano, G.; Vassalli, G. Beneficial effects of exosomes secreted by cardiac-derived progenitor cells and other cell types in myocardial ischemia. *Stem Cell Investig.* 2017, 4, 93. [CrossRef] [PubMed]

13. Prathipati, P.; Nandi, S.S.; Mishra, P.K. Stem Cell-Derived Exosomes, Autophagy, Extracellular Matrix Turnover, and miRNAs in Cardiac Regeneration during Stem Cell Therapy. *Stem Cell Rev.* 2017, 13, 79–91. [CrossRef] [PubMed]

14. Khan, M.; Nickoloff, E.; Abramova, T.; Johnson, J.; Verma, S.K.; Krishnamurthy, P.; Mackie, A.R.; Vaughan, E.; Garikipati, V.N.; Benedict, C.; et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. *Circ. Res.* 2015, 117, 56–62. [CrossRef]

15. Sahoo, S.; Losordo, D.W. Exosomes and cardiac repair after myocardial infarction. *Circ. Res.* 2014, 114, 333–344. [CrossRef]

16. Kervadec, A.; Bellamy, V.; El Harane, N.; Arakelian, L.; Vanneau, V.; Cacciapuoti, I.; Nemetalla, H.; Perier, M.C.; Toeg, H.D.; Richart, A.; et al. Cardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure. *J. Heart Lung Transplant.* 2016, 35, 795–807. [CrossRef]

17. Vlassov, A.V.; Magdaleno, S.; Setterquist, R.; Conrad, R. Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. *Biochim. Biophys. Acta.* 2012, 1820, 940–948. [CrossRef]
20. Valadi, H.; Ekstrom, K.; Bossios, A.; Sjostrand, M.; Lee, J.J.; Lotvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.* **2007**, *9*, 654–659. [CrossRef]

21. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. *Cell* **2009**, *136*, 215–233. [CrossRef] [PubMed]

22. Wang, S.; Aurora, A.B.; Johnson, B.A.; Qi, X.; McNally, J.; Hill, J.A.; Richardson, J.A.; Bassel-Duby, R.; Olson, E.N. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. *Dev. Cell* **2008**, *15*, 261–271. [CrossRef] [PubMed]

23. Mocharla, P.; Briand, S.; Giannotti, G.; Dorries, C.; Jakob, P.; Paneni, F.; Luscher, T.; Landmesser, U. AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: Role for proangiogenic effects and alterations in type 2 diabetes. *Blood* **2013**, *121*, 226–236. [CrossRef] [PubMed]

24. Mocharla, P.; Briand, S.; Giannotti, G.; Dorries, C.; Jakob, P.; Paneni, F.; Luscher, T.; Landmesser, U. AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: Role for proangiogenic effects and alterations in type 2 diabetes. *Blood* **2013**, *121*, 226–236. [CrossRef] [PubMed]

25. Kong, L.; Du, X.; Hu, N.; Li, W.; Wang, W.; Wei, S.; Zhuang, H.; Li, X.; Li, C. Downregulation of let-7e-5p contributes to endothelial progenitor cell dysfunction in deep vein thrombosis via targeting FASLG. *Thromb. Res.* **2016**, *138*, 30–36. [CrossRef]

26. Namazi, H.; Mohit, E.; Namazi, I.; Rajabi, S.; Samadian, A.; Hajizadeh-Saffar, E.; Aghdami, N.; Baharvand, H. Exosomes secreted by hypoxic cardiomyocyte-derived cells enhance tube formation and increase pro-angiogenic microRNA. *J. Cell. Biochem.* **2018**, *119*, 4150–4160. [CrossRef]

27. Feng, Y.; Huang, W.; Wani, M.; Yu, X.; Ashraf, M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mepc2 via miR-22. *PLoS ONE* **2014**, *9*, e88685. [CrossRef]

28. Zhu, J.; Lu, K.; Zhang, N.; Zhao, Y.; Ma, Q.; Shen, J.; Lin, Y.; Xiang, P.; Tang, Y.; Hu, X.; et al. Myocardial reparative functions of exosomes from mesenchymal stem cells are enhanced by hypoxia treatment of the cells via transferring microRNA-210 in an nSMase2-dependent way. *Artif. Cells Nanomed. Biotecnol.* **2018**, *46*, 1659–1670. [CrossRef]

29. Luther, K.M.; Haar, L.; McGuinness, M.; Wang, Y.; Lynch Iv, T.L.; Phan, A.; Song, Y.; Shen, Z.; Gardner, G.; Kuffel, G.; et al. Exosomal miR-21a-5p mediates cardioprotection by mesenchymal stem cells. *J. Mol. Cell Cardiol.* **2018**, *119*, 125–137. [CrossRef]

30. Luo, Q.; Guo, D.; Liu, G.; Chen, G.; Hang, M.; Jin, M. Exosomes from MiR-126-Overexpressing Adscs Are Therapeutic in Relieving Acute Myocardial Ischaemic Injury. *Cell Physiol. Biochem*. **2017**, *44*, 2105–2116. [CrossRef]

31. Malek Mohammadi, M.; Kattih, B.; Grund, A.; Froese, N.; Korf-Klingebiel, M.; Gigina, A.; Schrameck, U.; Rudat, C.; Liang, Q.; Kispert, A.; et al. The transcription factor GATA4 promotes myocardial regeneration in neonatal mice. *EMBO Mol. Med.* **2017**, *9*, 265–279. [CrossRef] [PubMed]

32. Yu, W.; Huang, X.; Tian, X.; Zhang, H.; He, L.; Wang, Y.; Nie, Y.; Hu, S.; Lin, Z.; Zhou, B.; et al. GATA4 regulates Fgf16 to promote angiogenesis by transferring miR-125a. *Oncotarget* **2017**, *8*, 226–236. [CrossRef] [PubMed]

33. Rysa, J.; Tenhunen, O.; Serpi, R.; Soini, Y.; Nemer, M.; Leskinen, H.; Ruskoaho, H. GATA-4 overexpression is partially mediated by regulation of the miR-15 family. *Circ. Heart Fail.* **2010**, *3*, 440–450. [CrossRef] [PubMed]

34. Yu, B.; Gong, M.; He, Z.; Wang, Y.G.; Millard, R.W.; Ashraf, M.; Xu, M. Enhanced mesenchymal stem cell survival induced by GATA-4 overexpression is partially mediated by the miR-15 family. *Int. J. Biochem. Cell Biol*. **2013**, *45*, 2724–2735. [CrossRef]

35. Li, H.; Zuo, S.; Pasha, Z.; Yu, B.; He, Z.; Wang, Y.; Yang, X.; Ashraf, M.; Xu, M. GATA-4 promotes myocardial transdifferentiation of mesenchymal stromal cells via up-regulating IGFBP-4. *Cytotherapy* **2011**, *13*, 1057–1065. [CrossRef]

36. Gong, M.; Yu, B.; Wang, J.; Liu, M.; Paul, C.; Millard, R.W.; Xiao, D.S.; Ashraf, M.; Xu, M. Mesenchymal stem cells release exosomes that transfer miRNAs to endothelial cells and promote angiogenesis. *Oncotarget* **2017**, *8*, 45200–45212. [CrossRef]

37. Kang, K.; Ma, R.; Cai, W.; Huang, W.; Paul, C.; Liang, J.; Wang, Y.; Zhao, T.; Kim, H.W.; Xu, M.; et al. Exosomes Secreted from CXCR4 Overexpressing Mesenchymal Stem Cells Promote Cardioprotection via Akt Signaling Pathway following Myocardial Infarction. *Stem Cells Int.* **2015**, *2015*, 659890. [CrossRef]

38. Ma, J.; Zhao, Y.; Sun, L.; Sun, X.; Zhao, X.; Sun, Q.; Xin, H.; Xu, W.; Zhu, W. Exosomes Derived from Akt-Modified Human Umbilical Cord Mesenchymal Stem Cells Improve Cardiac Regeneration and Promote Angiogenesis via Activating Platelet-Derived Growth Factor D. *Stem Cells Transl. Med.* **2017**, *6*, 51–59. [CrossRef]

39. Bhat, S.; Zhang, L.; Duan, L.; Wang, X.; Min, Y.; Yu, H. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. *J. Mol. Med.* **2014**, *92*, 387–397. [CrossRef]

40. Zhang, Z.; Yang, J.; Yan, W.; Li, Y.; Shen, Z.; Asahara, T. Pretreatment of Cardiac Stem Cells With Exosomes Derived From Mesenchymal Stem Cells Enhances Cardiac Repair. *J. Am. Heart Assoc.* **2016**, *5*, e002856. [CrossRef]

41. Liang, X.; Zhang, L.; Wang, S.; Han, Q.; Zhao, R.C. Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125A. *J. Cell Sci.* **2016**, *129*, 2182–2189. [CrossRef] [PubMed]

42. Shabbir, A.; Cox, A.; Rodriguez-Moncal, L.; Salgado, M.; Van Badiavas, E. Mesenchymal Stem Cell Exosomes Induce Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In Vitro. *Stem Cells Dev.* **2015**, *24*, 1635–1647. [CrossRef] [PubMed]

43. Karttunen, J.; Heiskanen, M.; Navarro-Ferrandis, V.; Das Gupta, S.; Lipponen, A.; Puhakka, N.; Rilla, K.; Koistinen, A.; Pitkänen, A. Precipitation-based extracellular vesicle isolation from rat plasma co-precipitate vesicle-free microRNAs. *J. Extracell. Vesicles* **2019**, *8*, 1555410. [CrossRef] [PubMed]
44. Gamez-Valero, A.; Monguio-Tortajada, M.; Carreras-Planella, L.; Franquesa, M.; Beyer, K.; Borras, F.E. Size-Exclusion Chromatography-based isolation minimally alters Extracellular Vesicles' characteristics compared to precipitating agents. Sci. Rep. 2016, 6, 35641. [CrossRef] [PubMed]

45. Hu, S.; Huang, M.; Li, Z.; Jia, F.; Ghosh, Z.; Lijkwan, M.A.; Fasanaro, P.; Sun, N.; Wang, X.; Martelli, F.; et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010, 122, S124–S131. [CrossRef] [PubMed]

46. Katare, R.; Riu, F.; Mitchell, K.; Gubernator, M.; Campagnolo, P.; Cui, Y.; Fortunato, O.; Avolio, E.; Cesselli, D.; Beltrami, A.P.; et al. Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. Circ. Res. 2011, 109, 894–906. [CrossRef]

47. Ouyang, B.; Xie, Y.; Zhang, C.; Deng, C.; Lv, L.; Yao, J.; Zhang, Y.; Liu, G.; Deng, J.; Deng, C. Extracellular Vesicles From Human Urine-Derived Stem Cells Ameliorate Erectile Dysfunction in a Diabetic Rat Model by Delivering Proangiogenic MicroRNA. Sex. Med. 2019, 7, 241–250. [CrossRef]

48. He, J.G.; Li, H.R.; Han, J.X.; Li, B.B.; Yan, D.; Li, H.Y.; Wang, P.; Luo, Y. GATA-4-expressing mouse bone marrow mesenchymal stem cells improve cardiac function after myocardial infarction via secreted exosomes. Sci. Rep. 2018, 8, 9047. [CrossRef]

49. Xiang, W.; Tian, C.; Peng, S.; Zhou, L.; Pan, S.; Deng, Z. Let-7i attenuates human brain microvascular endothelial cell damage in oxygen glucose deprivation model by decreasing toll-like receptor 4 expression. Biochem. Biophys. Res. Commun. 2017, 493, 788–793. [CrossRef]

50. Brennan, E.; Wang, B.; McClelland, A.; Mohan, M.; Marai, M.; Beuscart, O.; Derouiche, S.; Gray, S.; Pickering, R.; Tikellis, C.; et al. Protective Effect of let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis. Diabetes 2017, 66, 2266–2277. [CrossRef]

51. Ding, Z.; Wang, X.; Schnackenberg, L.; Khaidakov, M.; Liu, S.; Singla, S.; Dai, Y.; Mehta, J.L. Regulation of autophagy and apoptosis in response to ox-LDL in vascular smooth muscle cells, and the modulatory effects of the microRNA hsa-let-7 g. Int. J. Cardiol. 2013, 168, 1378–1385. [CrossRef] [PubMed]

52. Colombo, G.; Margosio, B.; Ragona, L.; Neves, M.; Bonifacio, S.; Annis, D.S.; Stravalaci, M.; Tomaselli, S.; Giavazzi, R.; Rusnati, M.; et al. Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: An integrated strategy for the development of new antiangiogenic compounds. J. Biol. Chem. 2010, 285, 8733–8742. [CrossRef] [PubMed]

53. Taraboletti, G.; Roberts, D.; Liotta, L.A.; Giavazzi, R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: A potential angiogenesis regulatory factor. J. Cell Biol. 1990, 111, 765–772. [CrossRef] [PubMed]

54. Zhang, X.; Kazerounian, S.; Duquette, M.; Perruzzi, C.; Nagy, J.A.; Dvorak, H.F.; Parangi, S.; Lawler, J. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J. 2009, 23, 3368–3376. [CrossRef]

55. Lawler, P.R.; Lawler, J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb. Perspect. Med. 2012, 2, a006627. [CrossRef]